Hydrochloric Acid → 2-Amino-5-[1-[4-(piperidin-4-yloxy)-quinolin-6-yl]-meth-(z)-ylidene]-thiazol-4-one
Reaktionsgleichung
C(OC([N:8]1[CH2:13][CH2:12][CH:11]([O:14][C:15]2[C:24]3[C:19](=[CH:20][CH:21]=[C:22](/[CH:25]=[C:26]4/[C:27](=[O:32])[N:28]=[C:29]([NH2:31])[S:30]/4)[CH:23]=3)[N:18]=[CH:17][CH:16]=2)[CH2:10][CH2:9]1)=O)(C)(C)C.Cl>ClCCl>[NH2:31][C:29]1[S:30]/[C:26](=[CH:25]\[C:22]2[CH:23]=[C:24]3[C:19](=[CH:20][CH:21]=2)[N:18]=[CH:17][CH:16]=[C:15]3[O:14][CH:11]2[CH2:10][CH2:9][NH:8][CH2:13][CH2:12]2)/[C:27](=[O:32])[N:28]=1Komponenten
4
Edukt 2
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 1
Versuchsvorschrift
The suspension of 4-{6-[2-amino-4-oxo-4H-thiazol-(5Z)-ylidenemethyl]-quinolin-4-yloxy}-piperidine-1-carboxylic acid tert-butyl ester (70 mg, 0.15 mmol) in dichloromethane (1 ml) was treated with hydrogen chloride (in 1,4-dioxane, 4M, 1 ml) for 1.5 hr at room temperature. After removing the solvent, the obtained solid was treated with either. Ion exchange extraction chromatography (Cation exchanger: benenesulfonic acid, 2 g/6 ml, 1M ammonia in methanol and dichloromethane) afforded the free base form of 2-Amino-5-[1-[4-(piperidin-4-yloxy)-quinolin-6-yl]-meth-(Z)-ylidene]-thiazol-4-one. LC-MS m/e 355 (MH+).